#MSTC – With and without #Scrappagepolicy

Scenario 1 – No Scrappage Policy

As promised by management, MSTC will be able to clean up the balance sheet by Sep’21. Trading business is already closed. FSNL divestment has started by DIPAM.
Post Sep’21, MSTC may have around 800 crs cash (assuming 300 crs proceeds from FSNL) in the BS, Rs 115 per share..

It will have E-Comm as the only business with multiple opportunities which are detailed in the note attached below..
Ex cash RoCE will be 50% plus with growth rate of 15-20% for E-Comm business with 250 crs topline and 100 crs PAT (excl. other income) for FY22. Estimated EPS of Rs 15 for core E-comm business.

At 15x PE for core E-Comm value = 15x15 + 115 = 340…
At 20x, it would be 415..
Scenario 2 – Scrappage Policy

There are 24 Mn end-of-life vehicles in India with average age of car being 18 yrs. Total 6 Mn ton steel scrap imported by India. Report says, Scrappage policy can generate 40,000 cr scrap annually. #MSTC has two benefits..
1 – Mahindra Cero (50:50 JV with MSTC) is only authorized scrap recycling company today with 4 centers. It plans to set up 25 centers once the policy is announced and further can expand to 50. Assuming 5000 crs (8% market share and average 100 crs per center) revenue in 5 years
and 7% NPM, it can generate 350 crs PAT after 5 yrs, contributing 175 crs to MSTC PAT.

2 – Assuming 10,000 crs (25% market share) scrap getting auctioned on MSTC platform and 2% fees, it can generate 200 crs additional revenue and 150 crs additional PAT for MSTC…
I tried to put all my assumptions upfront, one can play with the assumptions based on his understanding and arrive at his own valuation..

Disc. – This is not a reco…I am invested

drive.google.com/file/d/1SI4Hwr…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with jeevan patwa

jeevan patwa Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @jeevanpatwa

25 Dec 20
#Suven – Journey of my first 50 bagger…

I bought #Suven first in Apr 2013 around Rs 20…today after almost 7.5 years, its Rs 1000 (Suven pharma 920 adjusted for bonus + Suven Life 80)..CAGR of almost 68% for 7.5 years. I am fortunate to hold it throughout the journey and

1/n
add on multiple occasions on way up. Like to share my experience in this thread for everyone’s benefit..

First time I bought because I like the management focus on R&D. It had chosen the most difficult therapeutic area in pharma which is CNS and it was investing the cash

2/n
flow it used to earn from CRAMS. It also used to write off all the R&D expenses in the P&L instead of capitalizing it in BS. That gave me lot of comfort about management quality.

I kept on adding as funds keep coming. I remember giving a public presentation on Suven in

3/n
Read 10 tweets
15 Dec 20
#SuvenLife – Niche R&D play..very high risk and very high reward…key is right allocation…

Jazz Pharma was quoting around $0.5 in 2009, today its $150 and Mcap of $8.5 Bn on Nasdaq..almost 300x in 11 years. 80% of its total sales ($2.1 Bn) come from single drug Xyrem.
Axovant Lifescience, bought Alzheimer molecule from GSK, repackaged it and done phase-3 trials. Before starting the trials, the valuation was $2 Bn, just before announcing the data, it rose to $3 Bn. One of the leading broker put the target of $12 Bn if the trials succeeded..
but it failed in phase-3 trials. Current Mcap is $120 Mn…

This is R&D for New Chemical Entity (NCE)…very high risk and very high reward…

Brain-related illnesses, also known as CNS diseases, afflict more than 2 billion people worldwide. Diseases of the brain and mind range
Read 12 tweets
1 Nov 20
Suven Pharma – Becoming more relevant for customers…

“Crucial alliances were forged. Important investments were made. Strong associations sustained. We chose to widen our canvas. Heighten our vision”
“There is no API as of today. But we can manufacture APIs if our customers desire so”

“There is only one formulation as of today. Creating a basket of formulations for our CDMO customers could be an opportunity”
--- This is where Suven Pharma is moving to become more relevant for its customers…

It is only the penultimate intermediate until now. But straddling the phama value is the new customer mandate. Suven will be taking more wallet share of the customer by supplying the
Read 10 tweets
30 Oct 20
Laurus Labs – A process Innovator and a CRAMS player – deserves much higher multiple

With more than 100 process patents on his name, Dr Chhava has created a sustainable competitive advantage for Laurus Labs. Similar to drug innovator enjoying 15 years patent protection,
Laurus enjoys patent protection for its economically viable and innovative processes for different APIs like Efavirenz, Tenofovir, Dolutegravir, Metformin, Ivacaftor and many more..

Laurus developed novel and cost effective process for Efavirenz which reduced the cost by 50%...
Similar thing repeated when newer HIV regimen, Dolutegravir came into effect..Laurus developed its own proprietary novel and cost effective process for it..it is one of the few players having approval for TLE400...It has got process patent for Metformin where it can be
Read 9 tweets
29 Oct 20
Cloud & Digital – Multiple times bigger than Y2K for India…

Covid has accelerated cloud adoption in the world with more and more organization moving to cloud..Healthcare is shifting its data centers to cloud..patient records are getting moved to cloud..EHR software,
Strong results and management commentary from Accenture. Cloud services grew double digits..expect good nos from #IndianIT supported by cloud and digital services..
IT rally started... Mid cap IT will create new ATH
Read 5 tweets
30 Jul 20
Laurus Labs Q1FY21 results – My take – Operating leverage kicked in finally..Re-rating will follow..

When I bought Laurus Labs 2.5 years back, my hypothesis was…with the capacity that they put in ..it can generate 4000 crs top line and 15% NPM..
and I kept on asking management about the idle gross block in almost every conf. call…but the approvals got delayed and idle gross block was stationary..finally there was light at the end of tunnel…the hypothesis started playing out since Q4FY20…
formulation business started sweating…Depreciation, Interest, other fixed costs remained constant….Operating leverage kicked in finally….net profit swelled..
Read 10 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!